Shopping Cart
Evidence update 2026
Scientific evidence review
Ovarian insufficiency and intraovarian PRP: what does the evidence show in 2026?
Intraovarian platelet-rich plasma (PRP) is being investigated in women with diminished ovarian reserve and poor ovarian response. Individual studies report positive signals, but a consistent increase in live birth rates has not been demonstrated. The procedure therefore remains experimental.
This article reviews the evidence. It is not an individual treatment recommendation.
POI, DOR and POR are not the same
A clear distinction between patient groups is essential when interpreting the PRP literature. Many older studies combine these conditions even though prognosis, baseline characteristics and study endpoints differ.
Premature Ovarian Insufficiency (POI)
Loss or marked reduction of ovarian activity before age 40. Persistent menstrual disturbance and elevated FSH are typical findings.
Diminished Ovarian Reserve (DOR)
Reduced ovarian reserve. Low AMH or a low antral follicle count may be present while cycles and ovarian activity continue.
Poor Ovarian Response (POR)
Insufficient response to controlled ovarian stimulation, usually in the context of IVF.
Results from these groups cannot simply be transferred from one population to another.
How common is premature ovarian insufficiency?
Newer epidemiological data suggest a prevalence of around 3.5%. Older studies reported approximately 1%.
POI is also not identical to an irreversible menopause. Intermittent ovarian activity can occur in non-surgical POI; spontaneous ovulation and pregnancy are uncommon but not impossible.
Why is PRP being studied in the ovary?
PRP is prepared from autologous blood and contains an increased concentration of platelets. After activation, platelets can release growth factors and signalling proteins. This has led to the hypothesis that PRP could influence the local ovarian microenvironment, vascular supply or the function of remaining follicles.
Biological plausibility is not proof of clinical efficacy. There is no clinical evidence that PRP rebuilds an exhausted follicle pool or reverses the age-related genetic quality of oocytes.
There is no single standardized ovarian PRP protocol
Studies differ substantially in blood volume, anticoagulant, centrifugation, platelet concentration, leukocyte content, activation, injection volume and timing. In many publications, the achieved platelet concentration is not adequately reported. Positive findings from one protocol therefore cannot automatically be transferred to another PRP system.
From autologous blood to experimental ovarian use
Schematic illustration – not a standardized universal protocol
1
1. Blood collection
Autologous blood is collected as the starting material.
2
2. PRP preparation
Centrifugation and processing vary substantially between protocols.
3
3. Intraovarian use
Studies investigate puncture and injection into the ovary.
4
4. Clinical evaluation
Key outcomes are not only lab markers, but pregnancy and live birth.
Quick evidence overview
Biological plausibility exists
Observational studies often look more positive
RCTs do not show a uniform picture
A live-birth benefit is not established
What do randomized studies show?
| Study | Population / design | Main finding |
|---|---|---|
| Barrenetxea et al. 2024 | 60 women with POR; randomized controlled trial | More mature oocytes; no advantage in euploid blastocysts. In this study, the clinical pregnancy rate was lower in the PRP group than in the control group (27% vs. 60%); there was no statistically significant difference in full-term pregnancies. |
| PROVA / Herlihy et al. 2024 | 83 women under 38 with repeated POR | No significant advantage in mature oocytes, blastocysts, euploid blastocysts or sustained implantation. |
| Yahyaei et al. 2026 | 200 women with POR; randomized | Higher AFC and improved maturation/fertilization rates with higher pregnancy rates; live birth rate was higher but not statistically significant. |
| Barad et al., ESHRE 2026 Congress abstract / not yet a full peer-reviewed publication | PRP versus platelet-poor plasma | No advantage in embryo quality, ovarian response, hormonal markers or pregnancy. Congress abstract. |
| Maier-Eggersmann et al., ESHRE 2026 Congress abstract / not yet a full peer-reviewed publication | 114 women with low ovarian reserve; PRP versus saline | No significant advantage in oocyte yield, AMH, FSH, AFC, pregnancy or live birth. Congress abstract. |
The randomized evidence is therefore inconsistent. Some studies show signals for selected parameters, while others do not. A reproducible live-birth benefit has not yet been demonstrated.
Why do some meta-analyses look more positive?
The 2026 systematic review by Wang et al. included 19 prospective studies with 1,794 women. Only two were randomized controlled trials; most were cohort or before-and-after studies.
Uncontrolled analyses sometimes showed higher AMH, higher AFC or more mature oocytes after PRP. Without a control group, however, these changes cannot be attributed to PRP with confidence. Controlled analyses did not show a consistent advantage for pregnancy or live birth.
What do we know specifically about PRP in established POI?
The evidence for confirmed POI is weaker than for POR. Many studies described as POI studies also include women with DOR, POR, perimenopause or residual follicular activity. Results from such groups should not be generalized to women with established POI.
AMH and AFC are not the same as a live birth
Surrogate markers
- AMH
- FSH
- AFC
- Number of retrieved oocytes
Patient-relevant outcomes
- clinical pregnancy
- ongoing pregnancy
- live birth
Changes in AMH, FSH or AFC may be scientifically interesting, but they do not automatically prove a higher probability of live birth. This distinction is central to the interpretation of the current PRP evidence.
What are the risks of intraovarian PRP injection?
Intraovarian PRP is an invasive procedure.
The procedure involves puncture and injection into the ovary, often transvaginally under ultrasound guidance. Potential risks include pain, bleeding, infection, injury to adjacent structures and complications related to sedation or anesthesia.
Serious infectious complications such as ovarian or tubo-ovarian abscesses have now been reported after intraovarian PRP. Case reports do not establish frequency, but they do refute the assumption that an autologous blood product makes the procedure automatically risk-free.
What do current POI guidelines say?
The international evidence-based POI guideline states that no intervention has yet been reliably shown to restore ovarian activity or natural conception rates in POI. Intraovarian PRP is therefore not an established standard therapy for restoring fertility.
What should future research clarify?
Larger standardized randomized trials are needed, with clearly defined patient groups, reproducible PRP characterization and patient-relevant endpoints. Platelet concentration, leukocyte content, activation, injection volume, timing and longer safety follow-up should be documented.
How the evidence has evolved
2016
Early clinical reports of intraovarian PRP.
2019–2023
Mostly case series, cohorts and before-and-after studies – often positive, but methodologically limited.
2024
First important randomized trials with more mixed results.
2025
Further reviews and retrospective data; clearer separation of POI, DOR and POR.
2026
A larger RCT, new randomized ESHRE data and additional safety reports.
Frequently asked questions
Can PRP rejuvenate the ovaries?
True ovarian rejuvenation in the sense of rebuilding the follicle pool or reversing age-related genetic oocyte quality has not been demonstrated.
Can PRP increase AMH?
Some uncontrolled studies report changes in AMH. Controlled studies are inconsistent, and AMH is a biomarker rather than direct proof of a higher chance of pregnancy.
Does PRP increase pregnancy rates?
Randomized studies are conflicting. A reproducible advantage, especially for live birth, has not yet been demonstrated.
Is intraovarian PRP a standard treatment for POI?
No. It remains experimental and is not established in current POI guidelines as a standard fertility-restoring therapy.
Is the procedure non-invasive?
No. It involves puncture and injection into the ovary.
Scientific interpretation
Intraovarian PRP is a relevant research field with biological plausibility and some positive signals. However, the available randomized evidence is inconsistent. Robust evidence that PRP reliably increases live birth rates in POI, DOR or POR is still lacking. It should therefore be described as an experimental procedure, not as proven ovarian rejuvenation or restoration of fertility.
Sources and further reading
- ESHRE / ASRM / CRE-WHiRL / IMS – Evidence-based guideline: Premature Ovarian Insufficiency
- Barrenetxea et al. 2024 – Human Reproduction
- Herlihy et al. 2024 – PROVA randomized controlled trial
- Yahyaei et al. 2026 – Journal of Ovarian Research
- Wang et al. 2026 – Systematic Review and Meta-Analysis
- Barad et al. – ESHRE 2026 congress abstract
- Maier-Eggersmann et al. – ESHRE 2026 congress abstract
- Case report – bilateral ovarian abscesses / sepsis after ovarian PRP
- Kalinowska, Mobin & Babayev 2026 – Bilateral ovarian abscesses following PRP injection (F&S Reports)